XML 59 R18.htm IDEA: XBRL DOCUMENT v3.25.4
Research and Development Prepaid Expenses and Accrued Liabilities
12 Months Ended
Dec. 31, 2025
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Research and Development Prepaid Expenses and Accrued Liabilities Research and Development Prepaid Expenses and Accrued Liabilities
Included within prepaid expenses and other current assets at December 31, 2025 and 2024 is $3,996 and $8,338, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at December 31, 2025 and 2024 is $31,498 and $17,441, respectively, relating to research and development expenditures.

These amounts are determined based on the estimated costs to complete each study or activity related to the ongoing clinical trials for ivonescimab, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, accrued liabilities increase as the activities progress. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company’s operational knowledge of the work completed under those contracts.